サーモフィッシャーサイエンティフィック株式会社／Thermo Fisher Scientific K.K. Product Lineup

Olink Explore HT is a next-generation multiplex proteomics analysis platform that extracts an overwhelming amount of information from small sample volumes. It can simultaneously measure over 5,400 proteins from just 2 µL of diverse samples such as plasma, serum, and CSF, achieving 99.5% high specificity and reproducibility through its unique PEA (Proximity Extension Assay) technology. By combining an automated workflow with NGS readouts, it enables high-precision and efficient analysis, accommodating a wide range of research phases from biomarker discovery to clinical research and drug development. Furthermore, it has been adopted in The UK Biobank Pharma Proteomics Project, the largest human proteome study in the world, demonstrating its performance and reliability in large-scale research projects. In addition to the installation of the equipment in laboratories, it is also available through service providers and Olink analysis services, with our staff supporting the experimental design phase according to research objectives and analysis needs.

Olink Target 48 Neurodegeneration is a high-performance proteomics panel specialized in neurodegenerative disease research. It can simultaneously measure 41 types of proteins, including the latest and important central nervous system biomarkers such as Aß40, Aß42, pTau217, NfL, and GFAP, which are gaining attention in Alzheimer's and Parkinson's disease research. This panel enables the acquisition of absolute quantification (ng/mL) data, which is difficult with other technologies, allowing for data comparison between studies and institutions, as well as high reproducibility in long-term longitudinal studies. With just 1µL of plasma or cerebrospinal fluid, high-sensitivity measurements can be achieved, maximizing the use of valuable clinical samples. Furthermore, by combining analyses with Olink's cytokine panel, it comprehensively captures neurodegeneration and neuroinflammation, significantly enhancing analytical power. The standardized workflow using the Signature Q100 system contributes broadly from basic research to clinical and drug discovery research.

Olink's neurobiomarker analysis is a proteomics method that allows for the highly sensitive and specific simultaneous measurement of neurodegenerative disease-related proteins from limited samples such as plasma, serum, and cerebrospinal fluid, using Proximity Extension Assay (PEA) technology. Olink Target 48 Neurodegeneration enables the absolute quantification of markers important in neurodegenerative disease research, such as Aß40, Aß42, pTau217, NfL, and GFAP, making it useful for longitudinal studies and inter-facility comparisons. Furthermore, by using Olink Explore HT and Target 96 Neurology, a broad protein profiling analysis including neuroinflammation and synaptic function becomes possible, supporting the identification of novel biomarkers and elucidation of pathological mechanisms. **Effects of Implementation** - Promotion of understanding disease mechanisms through comprehensive analysis of neuroinflammation-related proteins. - Increased efficiency in biomarker discovery and contribution to drug development research. - Ability to measure numerous proteins from a small amount of sample, allowing for effective use of valuable samples.

■Connecting Biomarker Discovery to Clinical Application - Explained through Actual Cases of Neurodegenerative Diseases Although biomarkers are discovered, many do not reach clinical application. The reasons for this lie in multiple hurdles that arise after exploration, such as "narrowing down candidates," "reproducibility," and "connecting to clinical practice." 1. How should we narrow down promising candidates obtained from comprehensive exploration? 2. How can we ensure reproducibility and scalability? 3. What are the key points for a smooth transition to clinical research? 4. What should we be mindful of in terms of data science throughout the overall flow? In this online seminar, we will clearly explain specific strategies to advance from discovery to clinical application, based on actual research cases of Alzheimer's disease and multiple sclerosis, in an easy-to-understand manner in Japanese. 【Event Overview】 Date and Time: May 21, 2026 (Thursday) 16:00 - 17:00, with on-demand viewing available later Format: Zoom Webinar, Free of Charge How to View: Please register via "Click here to apply for the web seminar" or the URL in the basic information. (Note) Olink products are for research use only and cannot be used for diagnostic purposes.

Olink Reveal is a next-generation proteomics analysis solution that utilizes NGS. It can be operated with various existing next-generation sequencers (NGS) and streamlines drug discovery research and cohort studies. The protein list included can be downloaded from the related link site or you can contact us for more information. ■Features - Simultaneous measurement of approximately 1,000 proteins from just 4 µL of serum or plasma - "Mid-Plex" panel with an excellent balance of cost and information volume - Carefully selected markers of high clinical importance, including inflammation, cancer, and neurology - Supports multi-sample and large-scale studies based on NGS ■Benefits - Ideal for screening applications where Explore HT may be excessive - Efficient data acquisition suitable for hypothesis validation phases - Maintains consistency of data with other Olink panels through PEA technology ■Applications - Biomarker discovery and validation - Cohort studies and multi-omics analysis - Drug discovery and translational research